Key facts
- Notable investors include Flerie, Vinnova.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Bonsai Biotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Bonsai Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bonsai Biotherapeutics
Developer of tolerogen-based biological drugs designed to restore immune tolerance and provide disease-modifying relief for autoimmune conditions. The company offers a tolerogen platform that utilizes targeted immune reprogramming rather than broad immunosuppression, enabling clients to achieve long-lasting therapeutic balance while maintaining their normal immune system capacity.
- Sector
- Healthcare
- HQ
- Gothenburg, Sweden
- Founded
- 2025
- Employees
- 7
- Website
- bonsaibiotherapeutics.com/
- Ownership
- Privately Held (backing)
Bonsai Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bonsai Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bonsai Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.